Caladrius Biosciences Reports 2016 Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Caladrius Biosciences (CLBS) Reports Q3 Loss Per Share of $1.33
August 9, 2016 5:33 PM EDTCaladrius Biosciences (NASDAQ: CLBS) reported Q2 EPS of ($1.33), may not compare to the analyst estimate of ($1.75). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.53 million.
2016 Financial Guidance
The Company reaffirms its previous guidance as follows:
Consolidated... More